Phathom Pharmaceuticals (NASDAQ:PHAT) traded higher on Friday after Cantor Fitzgerald initiated its coverage with an overweight recommendation despite a recent selloff attributed to the company's ...

FLORHAM PARK, N.J., Jan. 29, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for ...

Gastroesophageal Reflux disease market Insights. DelveInsight's Gastroesophageal Reflux Disease Market report offers an in-depth understanding of the epide ...

Three years after it was formed as a spinout of Japanese drugmaker Takeda, Phathom Pharmaceuticals has racked up its first FDA approvals, and claimed a sizeable $260 million in new financing to ...

Rocket Pharmaceuticals (RCKT) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising ...